ArticleAngiogenesis2026
The vascular contribution to immunotherapy success.
Article in Angiogenesis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Angiogenesis represents a mechanism enabling tumors to evade immune surveillance. This immune escape is mediated, at least in part, by angiogenic factor-induced endothelial cell anergy, which suppresses leukocyte adhesion and infiltration into the tumor microenvironment. Consequently, it is becoming increasingly evident that the efficacy of immunotherapy can be improved by its combination with anti-angiogenic agents. Numerous studies, including clinical trials, have provided proof of this concept. A paper in this issue of Angiogenesis further substantiates this paradigm by demonstrating that normalizing the tumor vasculature and overcoming endothelial cell anergy also ameliorates the activity of CAR T cell therapy. Here, we place these findings into a broader mechanistic context and discuss their implications for combination treatment strategies.
Indexed as
Identifiers
41824162What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.